Technology Offerings

MD-2 Biomarker Enhances Cardiac Insufficiency Risk Assessment

According to the invention the approach of an easy risk assessment of patients with diagnosed cardiac insufficiency is based on the measurement of concentration of a pro-tein in whole blood called MD-2 by using the ELISA-technology. ELISA (Enzyme-Linked-Immunosorbent-Assay) is a common and standardized immunological assay for the detection of specific molecules in body liq-uids. It is well known that for cardiac degen-eration the activation of toll-like receptor-4 (TLR 4) is important. TLR 4 and MD-2 then form a receptor complex.
By the additional use of MD-2 biomarker to the “gold-standard” biomarker BNP for risk stratification of cardiac insufficiency, an in-crease of sensitivity and specificity regarding to the long-term survival can be realized. The used biomarker for this assay, is a MD-2 protein (also called LY96) which relates to the group of so-called “Immune response receptors”.

Further information: PDF

PVA Mecklenburg-Vorpommern AG
Phone: +49 (0)381 49747-38

Contact
Christian Tholen

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

Comments (0)

Write a comment